Myriad Genetics MYGN Institutional Ownership

Myriad Genetics Inc (NASDAQ:MYGN) has 195 institutional investors with active 13F positions as of June 2026.

• Their combined ownership stood at 95.5% of outstanding shares in June 2026, down from 227.4% in March 2026.
• Their total shares held in MYGN increased 19.11% from the prior quarter, while the number of investors in Myriad Genetics decreased 11.76% year over year.
• Of these 195 funds, 119 grew their exposure to Myriad Genetics, 57 cut back, and 19 maintained positions.
• In total, institutional investors held 90.51Mn shares in Myriad Genetics as of June 2026, up by 14.52Mn shares quarter on quarter, and up 6.22Mn shares year over year.
• As of June 30, 2026, the biggest holder of Myriad Genetics is BlackRock, Inc. at 10.89Mn shares, representing 11.49% of shares outstanding.
• The largest buyers of Myriad Genetics for the quarter ending June 2026 were Vestal Point Capital, LP (4.09Mn), BlackRock, Inc. (2.0Mn), Sixth Street Partners Management Company, L.P. (1.74Mn), MACKENZIE FINANCIAL CORP (1.54Mn), CITADEL ADVISORS LLC (1.08Mn).
• Top sellers of MYGN stock for the quarter ending June 2026 included HRT FINANCIAL LP (1.24Mn), Point72 Asset Management, L.P. (719.12K), Morgan Stanley (687.64K), Assenagon Asset Management S.A. (415.5K), UBS Group AG (408.82K).
• According to Business Quant data, leading holders of MYGN for June 2026 are BlackRock, Inc. (10.89Mn), MILLENNIUM MANAGEMENT LLC (6.62Mn), Vestal Point Capital, LP (5.74Mn), State Street Corp (4.99Mn), D. E. Shaw & Co., Inc. (4.58Mn), VANGUARD CAPITAL MANAGEMENT LLC (4.08Mn), ACADIAN ASSET MANAGEMENT LLC (3.13Mn), VANGUARD PORTFOLIO MANAGEMENT LLC (3.08Mn), AQR CAPITAL MANAGEMENT LLC (2.77Mn), Morgan Stanley (2.48Mn).